With Tecfidera, Biogen Idec Delivers Best MS Product Launch Yet
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec blew past Wall Street estimates in its first quarter of revenue for its new, oral multiple sclerosis drug. But the biotech attributed much of the unexpected upside to quick conversions from another of its MS products, Tysabri.